



Giaconda secures new financing facility

Giaconda is pleased to announce that it has successfully obtained a funding facility through Sydney Capital Partners for \$250,000.

This facility is secured and will provide the company with sufficient funding for its operations to progress its discussions with third parties for licensing and product development.

The funders will be granted a right to invest an amount equal to the facility limit into shares in the Company at a price which is calculated in part by the price of future capital raisings and the share price performance of the company.

Sydney Capital Partners will also now act as one of the company's key advisers in future fund raising and business strategy execution.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

About Giaconda Limited

Giaconda Limited is a biotechnology company involved in developing and licensing innovative and cost effective medical therapies in the field of gastroenterology. Giaconda's products are targeted towards the treatment of serious conditions that are not adequately addressed by any existing therapy. In this way, Giaconda's products are intended to satisfy these significant unmet medical needs of the gastrointestinal market. The Giaconda portfolio consists of five products, all of which are novel combinations of known compounds.

See www.giaconda.com

About Sydney Capital Partners

Sydney Capital Partners is a specialist investment banking firm focusing on implementing equity and debt strategies for listed and private Australian companies.

See www.sydneycapital.com

Enquiries to Alison Coutts – Sydney Capital Partners 02 8264 2486

GIACONDA LIMITED

Ground Floor, 44 East Street, Five Dock NSW 2046 Phone: [612] 9370 0069 Fax: [612] 9712 1469
email: info@giacondalimited.com ABN 68 108 088 517 www.giacondalimited.com

For personal use only